Protease activity as a prognostic factor for wound healing in venous leg ulcers
Referencias
Additional references
Ashby RL, Gabe R, Ali S, Adderly U, Bland JM, Cullum NA, et al. Clinical and cost‐effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial. Lancet 2014;383(9920):871‐9.
Ashcroft GS, Horan MA, Herrick SE, Tarnuzzer RW, Schultz GS, Ferguson MW. Age‐related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans. Cell and Tissue Research 1997;290(3):581‐91.
Augustin M, Brocatti LK, Rustenbach SJ, Schafer I, Herberger K. Cost‐of‐illness of leg ulcers in the community. International Wound Journal 2012;11(3):283‐92.
Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. Journal of Clinical Epidemiology 2015;68(6):627‐36.
Barrett S, Davis L, Edwards J, Fletcher J, Harding K, Jack L, et al. Protease diagnostic in wound care: round‐table meeting. Wounds UK 2011;7(4 (Suppl)):3‐10.
Barwell JR, Ghauri AS, Taylor M, Deacon J, Wakely C, Poskitt KR, et al. Risk factors for healing and recurrence of chronic venous leg ulcers. Phlebology: The Journal of Venous Disease 2000;15(2):49‐52.
Barwell JR, Taylor M, Deacon J, Davies C, Whyman MR, Poskitt KR. Ankle motility is a risk factor for healing of chronic venous leg ulcers. Phlebology: The Journal of Venous Disease 2001;16(1):38‐40.
Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair and Regeneration 2008;16(5):642‐8.
Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. British Medical Journal 1987;294(6584):1389‐91.
Chaby G, Senet P, Ganry O, Caudron A, Thuillier D, Debure C, et al. Prognostic factors associated with healing of venous leg ulcers: a multicentre, prospective, cohort study. British Journal of Dermatology 2013;169(5):1106–13.
Choa R, Rayatt S, Mahtani K. Marjolin's ulcer. BMJ 2015;350:h3997.
Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. BMJ 1988;296(6638):1726‐7.
Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random‐effects meta‐analysis of inconsistent effects: a time for change. Annals of Internal Medicine 2014;160(4):267‐70.
Cullen B, Smith R, McCulloch E, Silcock D, Morrisson L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair and Regeneration 2002;10(1):16‐25.
Cullen BM, inventor, Ethicon, Inc, assignee. Monitoring of wounds by measurement of protease and protease inhibitor levels in wound fluids. United States patent US 20080132468. 2006 March 23.
Cullum N, Buckley H, Dumville J, Hall J, Lamb K, Madden M, et al. Wounds research for patient benefit: a 5‐year programme of research. Programme Grants for Applied Research 2016;4(13):10.3310/pgfar04130.
Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. The role of ADAMs in disease pathophysiology. Clinica Chimica Acta 2009;403(1‐2):31‐6.
Dumville JC, Worthy G, Soares MO, Bland JM, Cullum N, Dowson C, et al. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers. Health Technology Assessment 2009;13(55):1‐182; iii‐iv.
Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Molecular Aspects of Medicine 2008;29(5):258‐89.
Fletcher J, Moffatt C, Partsch H, Vowden K, Vowden P. Principles of compression in venous disease: a practitioner’s guide to treatment and prevention of venous leg ulcers. Wounds International 2013. www.woundsinternational.com/media/issues/672/files/content_10802.pdf (accessed 21 February 2017).
Ghauri AS, Nyamekye IK. Leg ulceration: the importance of treating the underlying pathophysiology. Phlebology/Venous Forum of the Royal Society of Medicine 2010;25(Suppl 1):42‐51.
Gibson M, Serena TE, Bartle C, Bayliff S, Clark J, Cullen B, et al. Testing chronic wounds for EPA. The benefits of testing all wounds, whether assessed as healing or non‐healing. www.wounds‐uk.com/pdf/cases_11013_199.pdf (accessed 9 January 2017).
Gibson M, Bayliff SW, Cullen BM, inventors, Systagenix Wound Management IP Co, assignee. Wound prognosis. United States patent US 20140045761. 2014 February 13.
Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers ‐ an analysis of 1324 legs. European Journal of Vascular and Endovascular Surgery 2005;29(1):74‐7.
Graves N, Finlayson K, Gibb M, O'Reilly M, Edwards H. Modelling the economic benefits of gold standard care for chronic wounds in a community setting. Wound Practice and Research 2014;22(3):163‐8.
Grøndahl‐Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Danø K. Urokinase‐ and tissue‐type plasminogen activators in keratinocytes during wound reepithelialization in vivo. Journal of Investigative Dermatology 1988;90(6):790‐5.
Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380‐2.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines 7: rating the quality of evidence – inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302.
Hahm G, Glaser JJ, Elster EA. Biomarkers to predict wound healing: the future of complex war wound management. Plastic and Reconstructive Surgery 2011;127(Suppl 1):21S‐6S.
Hall J, Buckley HL, Lamb KA, Stubbs N, Saramago P, Dumville JC, et al. Point prevalence of complex wounds in a defined United Kingdom population. Wound Repair and Regeneration 2014;22(6):694‐700.
Harding K, Armstrong DG, Barrett S, Kaufman H, Lázaro‐Martínez JL, Mayer D, et al. International consensus. The role of proteases in wound diagnostics: an expert working group review. Wounds International 2011. woundchek.com/uploads/downloads/consensus_documents/Role‐of‐proteases‐in‐wound‐diagnostics‐International.pdf (accessed 21 February 2017).
Harrison MB, Van Den Kerkhof EG, Hopman WM, Graham ID, Carley ME, Nelson EA. The Canadian bandaging trial: evidence‐informed leg ulcer care and the effectiveness of two compression technologies. BMC Nursing 2011;10:20.
Hart J, Silcock D, Gunnigle S, Cullen B, Light ND, Watt PW. The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. International Journal of Biochemistry and Cell Biology 2002;34(12):1557–70.
Hayden JA, Côté P, Steenstra IA, Bombardier C, for the QUIPS‐LBP Working Group. Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. Journal of Clinical Epidemiology 2008;61(6):552‐60.
Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of Internal Medicine 2013;158(4):280‐6.
Hayden JA, Tougas ME, Riley R, Iles R, Pincus T. Individual recovery expectations and prognosis of outcomes in non‐specific low back pain: prognostic factor exemplar review. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011284]
Hemingway H, Marmot M. Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ 1999;318(7196):1460–7.
Herber OR, Schnepp W, Rieger MA. A systematic review on the impact of leg ulceration on patients' quality of life. Health and Quality of Life Outcomes 2007;5:44.
Iglesias C, Nelson EA, Cullum NA, Torgerson DJ, VenUS Team. VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technology Assessment 2004;8(29):iii, 1‐105.
Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870. [DOI: 10.1136/bmj.h870]
Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD001733.pub3]
Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biology 2015;16:113.
Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase‐9 to tissue inhibitor of matrix metalloproteinase‐1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair and Regeneration 2002;10(1):26‐37.
Lantis JC, Marston WA, Farber A, Kirsner RS, Zhang Y, Lee TD, et al. The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth‐arrested allogeneic keratinocytes and fibroblasts. Journal of Vascular Surgery 2013;58(2):433‐9.
Lazaro JL, Izzo V, Meaume S, Davies AH, Lobmann R, Uccioli L. Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence. Journal of Wound Care 2016;25(5):277‐87.
Liu Y, Min D, Bolton T, Nubé V, Twigg SM, Yue DK, et al. Increased matrix metalloproteinase‐9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care 2009;32(1):117‐9.
Löffek S, Schilling O, Franzke CW. Series 'matrix metalloproteinases in lung health and disease': biological role of matrix metalloproteinases: a critical balance. European Respiratory Journal 2011;38(1):191‐208.
Löffler MW, Schuster H, Bühler S, Beckert S. Wound fluid in diabetic foot ulceration: more than just an undefined soup?. International Journal of Lower Extremity Wounds 2013;12(2):113–29.
Madden M. Is research in chronic wound care focusing on the outcomes that matter most to patients?. British Sociological Association Annual Conference: Changing Society; 2014 April 23‐25; Leeds, UK. 2014:232.
Margolis DJ, Berlin JA, Strom BL. Risk factors associated with the failure of a venous leg ulcer to heal. Archives of Dermatology 1999;135(8):920‐6.
Margolis DJ, Allen‐Taylor L, Hoffstad O, Berlin JA. The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair and Regeneration 2004;12(2):163‐8.
McCarty SM, Cochrane CA, Clegg PD, Percival SL. The role of endogenous and exogenous enzymes in chronic wounds: a focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. Wound Repair and Regeneration 2012;20(2):125–36.
McCarty SM, Percival SL. Proteases and delayed wound healing. Advances in Wound Care 2013;2(8):438‐47.
Milic DJ, Zivic SS, Bogdanovic DC, Karanovic ND, Golubovic ZV. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. Journal of Vascular Surgery 2009;49(5):1242‐7.
Moffatt CJ, Doherty DC, Smithdale R, Franks PJ. Clinical predictors of leg ulcer healing. British Journal of Dermatology 2010;162(1):51–8.
Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F. Prevalence of leg ulceration in a London population. QJM: Monthly Journal of the Association of Physicians 2004;97(7):431‐7.
Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou PY. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP‐1 to TIMP‐1 is a predictor of wound healing. Diabetic Medicine 2008;25(4):419‐26.
Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase‐2, tissue inhibitor of matrix metalloproteinase‐2 and PDGF‐AA on the chronicity of venous leg ulcers. European Journal of Vascular and Endovascular Surgery 2006;31(3):306‐10.
Nelzén O, Berqvist D, Lindhagen A. Venous and non‐venous leg ulcers: clinical history and appearance in a population study. British Journal of Surgery 1994;81(2):182‐7.
Nelzén O. Prevalence of venous leg ulcer: the importance of the data collection method. Phlebolymphology 2008;15(4):143‐50.
National Institute for Health and Care Excellence (NICE). Woundchek Protease Status for assessing elevated protease status in chronic wounds. Medtech innovation briefing [MIB83]. October 2016. www.nice.org.uk/advice/mib83 (accessed 21 February 2017).
Norman G, Westby MJ, Stubbs N, Dumville JC, Cullum N. A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers. Cochrane Database of Systematic Reviews 2016, Issue 1. [DOI: 10.1002/14651858.CD011753]
Nwomeh BC, Liang HX, Diegelmann RF, Cohen IK, Yager DR. Dynamics of the matrix metalloproteinases MMP‐1 and MMP‐8 in acute open human dermal wounds. Wound Repair and Regeneration 1998;6(2):127‐34.
Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP‐8 is the predominant collagenase in healing wounds and nonhealing ulcers. Journal of Surgical Research 1999;81(2):189‐95.
O'Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000265.pub3]
O'Meara S, Al‐Kurdi D, Ologun Y, Ovington LG, Martyn‐St James M, Richardson R. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003557.pub5]
Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A. Proteolytic activity in leg ulcer exudate. Experimental Dermatology 1993;2(1):29‐37.
Patel S, Maheshwari A, Chandra A. Biomarkers for wound healing and their evaluation. Journal of Wound Care 2016;25(1):46‐55.
Percival SL, Hill KE, Williams DW, Hooper SJ, Thomas DW, Costerton JW. A review of the scientific evidence for biofilms in wounds. Wound Repair and Regeneration 2012;20(5):647–57.
Persoon A, Heinen MM, van der Vleuten CJ, de Rooji MJ, van de Kerkhof PC, van Achterberg T. Leg ulcers: a review of their impact on daily life. Journal of Clinical Nursing 2004;13(3):341‐54.
Pugliese DJ. Infection in venous leg ulcers: considerations for optimal management in the elderly. Drugs & Aging 2016;33(2):87‐96.
Quirk S, Tyrell DJ, inventors, Kimberley Clark Worldwide, Inc, assignee. Sensors and methods of detection for proteinase enzymes. United States patent US 20030119073. 2003 June 26.
Ragnarson Tennvall G, Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom. Wound Repair and Regeneration 2005;13(1):13‐8.
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta‐analyses. BMJ 2011;342:d549.
The ROBINS‐I tool (Risk Of Bias In Non‐randomized Studies ‐ of Interventions). sites.google.com/site/riskofbiastool/welcome/home (accessed 16 August 2017).
Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Scotton MF, Miot HA, Abbade LP. Factors that influence healing of chronic venous leg ulcers: a retrospective cohort. Anais Brasileiros de Dermatologia 2014;89(3):414‐22.
Serena T, Cullen B, Bayliff S, Gibson M, DeMarco D, Galbraith J, et al. Protease activity levels associated with healing status of chronic wounds. 2011. www.woundchek.com/uploads/downloads/posters_articles/Protease‐Activity‐Levels‐Associated‐with‐Healing‐Status‐of‐Chronic‐Wounds.pdf (accessed 21 February 2017).
Serra R, Buffone G, Falcone D, Molinari V, Scaramuzzino M, Gallelle L, et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases‐9 and neutrophilgelatinase‐associated lipocalin. Wound Repair and Regeneration 2013;21(3):395‐401.
Sibbald RG, Contreras‐Ruiz J, Coutts P, Fierheller M, Rothman A, Woo K. Bacteriology, inflammation, and healing: a study of nanocrystalline silver dressings in chronic venous leg ulcers. Advances in Skin & Wound Care 2007;20(10):549‐58.
Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic venous leg ulcers. Clinical guideline 120. August 2010. www.sign.ac.uk/guidelines/fulltext/120/ (accessed 21 February 2017).
Snyder RJ, Driver V, Fife CE, Lantis J, Peirce B, Serena T, et al. Using a diagnostic tool to identify elevated protease activity levels in chronic and stalled wounds: a consensus panel discussion. Ostomy/Wound Management 2011;57(12):36‐46.
Snyder RJ, Cullen B, Nisbet LT. An audit to assess the perspectives of US wound care specialists regarding the importance of proteases in wound healing and wound assessment. International Wound Journal 2013;10(6):653‐60.
Srinivasaiah N, Dugdall H, Barrett S, Drew PJ. A point prevalence survey of wounds in north‐east England. Journal of Wound Care 2007;16(10):413‐9.
Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ 2016;355:i4919. [DOI: 10.1136/bmj.i4919]
Strimbu K, Tavel JA. What are biomarkers?. Current Opinion in HIV and AIDS 2010;5(6):463‐6.
Suleman L. Extracellular bacterial proteases in chronic wounds: a potential therapeutic target?. Advances in Wound Care 2016;5(10):455‐63.
Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. Journal of Clinical Epidemiology 2002;55(9):893‐9.
Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair and Regeneration 1999;7(6):442‐52.
Valencia IC, Falabella A, Kirsner RS, Eaglestein WH. Chronic venous insufficiency and venous leg ulceration. Journal of the American Academy of Dermatology 2001;44:401‐21.
Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. Journal of International Medical Research 2009;37(5):1528‐42.
Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. International Journal of Cancer 2002;99(2):157‐66.
Vlajinac H, Marinkovic J, Maksimovic M, Radak D. Factors related to venous ulceration: a cross‐sectional study. Angiology 2014;65(9):824‐30.
Vowden KR, Vowden P. The prevalence, management and outcome for acute wounds identified in a wound care survey within one English health care district. Journal of Tissue Viability 2009;18(1):7‐12.
Westby MJ, Norman G, Dumville JC, Stubbs N, Cullum N. Protease‐modulating matrix treatments for healing venous leg ulcers. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD011918.pub2]
Wlaschek M, Peus D, Achterberg V, Meyer‐Ingold W, Scharffetter‐Kochanek K. Protease inhibitors protect growth factor activity in chronic wounds. British Journal of Dermatology 1997;137(4):646‐63.
Wysocki A, Staiano‐Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP‐2 and MMP‐9. Journal of Investigative Dermatology 1993;101(1):64‐8.
Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair and Regeneration 1997;5(1):23‐32.
Yager DR, Kulina RA, Gilman LA. Wound fluids: a window Into the wound environment?. International Journal of Lower Extremity Wounds 2007;6(4):262‐72.
Zhang G. Protease assays. Assay guidance manual. Updated 31 March 2017. www.ncbi.nlm.nih.gov/books/NBK53196/pdf/Bookshelf_NBK53196.pdf (accessed 22 May 2017).
Figuras y tablas -
Figure 1
Prognostic factors for healing VLUs: person characteristics
Figuras y tablas -
Figure 2
Prognostic factors for VLU healing: wound characteristics 1
Figuras y tablas -
Figure 3
Prognostic factors for VLU healing: wound characteristics 2
Figuras y tablas -
Figure 4
Prognostic factors for VLU healing: number of ulcers
Figuras y tablas -
Figure 5
Prognostic factors for VLU healing: mobility and ankle flexion
Figuras y tablas -
Figure 6
Prognostic factors for VLU healing: bacteria and infection
